125 related articles for article (PubMed ID: 8847133)
1. Clinical usefulness of free PSA fraction as an indicator of prostate cancer.
Filella X; Alcover J; Molina R; Giménez N; Rodríguez A; Jo J; Carretero P; Ballesta AM
Int J Cancer; 1995 Dec; 63(6):780-4. PubMed ID: 8847133
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of PSA and its fractions in the diagnosis of prostate cancer].
Filella X; Truan D; Alcover J; Molina R; Luque P; Coca F; Ballesta AM
Med Clin (Barc); 2004 Feb; 122(7):241-4. PubMed ID: 15012870
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
4. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
5. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of prostate-specific antigen density as a diagnostic test of prostate cancer.
Filella X; Alcover J; Molina R; Carrere W; Carretero P; Ballesta AM
Tumour Biol; 1996; 17(1):20-6. PubMed ID: 7501969
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
8. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
9. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
10. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
11. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
12. [German Cancer Society e.V. S3 guideline for PSA determination in diagnosis of prostatic carcinoma].
Rübben H; Schalkhäuser K; Wolff J; Luboldt HJ;
Onkologie; 2003 Feb; 26(1):88-9. PubMed ID: 12661558
[No Abstract] [Full Text] [Related]
13. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
14. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.
Christensson A; Björk T; Nilsson O; Dahlén U; Matikainen MT; Cockett AT; Abrahamsson PA; Lilja H
J Urol; 1993 Jul; 150(1):100-5. PubMed ID: 7685416
[TBL] [Abstract][Full Text] [Related]
15. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
[TBL] [Abstract][Full Text] [Related]
16. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
18. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
[TBL] [Abstract][Full Text] [Related]
19. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
20. Early management of prostate cancer: how to respond to an elevated PSA?
Canto EI; Slawin KM
Annu Rev Med; 2002; 53():355-68. PubMed ID: 11818479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
